Previous Close | 23.68 |
Open | 24.08 |
Bid | 23.03 x 800 |
Ask | 26.45 x 1300 |
Day's Range | 22.89 - 24.08 |
52 Week Range | 19.34 - 96.88 |
Volume | |
Avg. Volume | 932,587 |
Market Cap | 1.25B |
Beta (5Y Monthly) | 0.81 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.95 |
Earnings Date | Jul 27, 2022 - Aug 01, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 59.00 |
SOUTH SAN FRANCISCO, Calif., June 21, 2022--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the release of its first environmental, social and governance (ESG) report.
SOUTH SAN FRANCISCO, Calif., June 02, 2022--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company will participate in the Jefferies Healthcare Conference on June 9th, 2022.
SOUTH SAN FRANCISCO, Calif., June 02, 2022--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it plans to expand its growing multimodality portfolio with AiKidney™, a new allograft risk assessment clinical decision support tool, in development, that includes AlloSure® and other transplant metrics.